Tags : UPLIZNA (inebilizumab-cdon)

Clinical Trials

Horizon Presents Results of Uplizna (inebilizumab-cdon) in N-MOmentum Trial for

Shots: The company reported the data from the N-MOmentum trial involves assessing Uplizna in patients with NMOSD The results from the N-MOmentum trial demonstrated a reduction in pain, long-term safety, and efficacy outcomes. Additional results from the new survey demonstrated NMOSD patient attitudes towards diagnosis and treatment Uplizna is the first FDA-approved B-cell depleter to […]Read More